Caribou Biosciences, Inc. (CRBU) stock
CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3073% below fair value
$0.35−0.01 (-2.51%)
Close on Nov 16, 2026Market cap $37.82MP/E –Yield –
Caribou Biosciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Caribou Biosciences's ebitda for the twelve months ending Jun 30, 2026 was -$106.89M. For fiscal 2025 it was -$144.70M. The highest annual figure on record is -$33.55M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$144.70M | – |
| FY2024 | Dec 31, 2024 | -$162.69M | – |
| FY2023 | Dec 31, 2023 | -$112.53M | – |
| FY2022 | Dec 31, 2022 | -$104.78M | – |
| FY2021 | Dec 31, 2021 | -$66.00M | – |
| FY2020 | Dec 31, 2020 | -$35.22M | – |
| FY2019 | Dec 31, 2019 | -$33.55M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$24.71M | – |
| Q1 FY2026 | Mar 31, 2026 | -$25.63M | – |
| Q4 FY2025 | Dec 31, 2025 | -$27.77M | – |
| Q3 FY2025 | Sep 30, 2025 | -$28.77M | – |
| Q2 FY2025 | Jun 30, 2025 | -$46.41M | – |
| Q1 FY2025 | Mar 31, 2025 | -$41.75M | – |
| Q4 FY2024 | Dec 31, 2024 | -$37.69M | – |
| Q3 FY2024 | Sep 30, 2024 | -$37.06M | – |
| Q2 FY2024 | Jun 30, 2024 | -$42.65M | – |
| Q1 FY2024 | Mar 31, 2024 | -$45.29M | – |
| Q4 FY2023 | Dec 31, 2023 | -$36.70M | – |
| Q3 FY2023 | Sep 30, 2023 | -$13.05M | – |
| Q2 FY2023 | Jun 30, 2023 | -$32.25M | – |
| Q1 FY2023 | Mar 31, 2023 | -$30.53M | – |
| Q4 FY2022 | Dec 31, 2022 | -$30.07M | – |
| Q3 FY2022 | Sep 30, 2022 | -$26.09M | – |
| Q2 FY2022 | Jun 30, 2022 | -$28.07M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.55M | – |
| Q4 FY2021 | Dec 31, 2021 | -$20.13M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.36M | – |
| Q2 FY2021 | Jun 30, 2021 | -$15.73M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.95M | – |
| Q4 FY2020 | Dec 31, 2020 | -$14.99M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.00M | – |
See a number that looks wrong?